The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion Recommending The Expanded Approval Of Regeneron Pharmaceuticals/Sanofi's Dupixent (Dupilumab) For Eosinophilic Esophagitis In Children Down To 1 Year Of Age
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the expanded approval of Regeneron Pharmaceuticals and Sanofi's Dupixent for treating eosinophilic esophagitis in children as young as 1 year old.
September 20, 2024 | 11:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals received a positive recommendation from the EMA for the expanded use of Dupixent, which could lead to increased market potential and revenue.
The EMA's positive opinion on Dupixent for younger children expands its potential market, likely increasing sales and revenue for Regeneron. This regulatory milestone is significant for the company's growth.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Sanofi, in collaboration with Regeneron, received a positive EMA recommendation for Dupixent, potentially enhancing its market presence and revenue.
The EMA's recommendation for Dupixent's expanded use in children could lead to increased sales and market share for Sanofi, enhancing its revenue prospects.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80